Global Brands for the Nutraceutical and Wellness Markets
This Relevium Technologies Inc. profile is part of a paid investor education campaign.*
Relevium Technologies Inc. (TSXV:RLV,OTCQB:RLLVF,FWB:6BX) is a wellness portfolio company that currently operates through two wholly-owned subsidiaries: BGX e-Health and Biocannabix Health Corporation.
BGX e-Health LLC, based in Orlando, Florida seeks to acquire and operate e-retail brands in the health and wellness space in order to build a portfolio which it can innovate through the introduction of high growth and trending products.
The company currently operates through three major brands: Bioganix®, PushandPullsystem® and LeefyLyfe®, which on a combined basis offer a variety of health, skincare and fitness supplements for the health and wellness market. The subsidiary generates over $1 million in revenue per quarter and has a well-defined distribution network throughout the US that includes large online retailers such as Amazon (NASDAQ:AMZN) and Walmart (NYSE:WMT). In total, the company has 58 SKUs under the BioGanix brand as well as an aloe vera-based brand of anti-aging cosmeceutical products that target Hispanic women in the US.
Biocannabix Health Corporation Inc., based in Montreal, Quebec is an integrated biopharma company focused on endo-cannabinoid medicine for pediatric applications. The company is building a global ecosystem of science, manufacturing and distribution that includes Canada, Colombia and Europe.
Biocannabix develops proprietary formulations serving the pediatric and adult medical markets with nutraceutical and pharmaceutical cannabinoid products. Biocannabix has signed an agreement to acquire 100% ownership of Weedsense Inc., a late-stage applicant for standard processing and medical sales license based in Montreal, Quebec. Once complete, the facility is expected to house Relevium’s distribution of cannabis products.
“Our investment into Weedsense provides Biocannabix with the capability to import, export, warehouse, package and sell to pharmacies and hospitals in a secure and compliant manner. This is another milestone in our vertically-integrated model for the pediatrics market,” stated Relevium CEO Aurelio Useche.
Biocannabix is also in the process of acquiring Lifeline Pharma SAS, a cultivation and extraction company in Cali, Colombia. Lifeline is in the process of securing three licenses which include extraction and manufacturing, cultivation with THC and non-psychoactive cultivation. The license would also allow domestic sales in Colombia, the exportation of cannabis and to conduct domestic scientific research. Lifeline Pharma will be building an EU-GMP extraction facility and has the option to construct up to 2.6 million-square-feet of cultivation space and full registration of 668 genetic strains with the Instituto Colombiano Agropecuario (ICA).
Relevium’s wholly-owned subsidiary Biocannabix has also secured a Canadian licensing agreement for Cannakids’ intellectual property (IP). Cannakids is a leader in medical cannabis patient research as well as pediatric and adult consumer product development. The license allows Relevium to build upon Cannakids’ existing infrastructure and standard operating procedures as the company rolls out the brand in Canada.
Relevium Technologies’ Company Highlights
- Relevium operates in the CPG health and wellness market, which in 2017 reached $4.2 trillion.
- Global cannabinoid market is expected to surpass $31 billion by 2021.
- Global nutraceutical market to reach US$578.23 billion by 2025.
- Vast distribution network through industry giants like Walmart and Amazon.
- Relevium signed an agreement to acquire a late-stage applicant for standard processing and medical sales license in Canada, facilitating the company’s entrance into Canada.
- Lifeline acquisition is expected to provide Relevium with an EU-GMP extraction facility, up to six million-square-feet of cultivation space and three licenses with scientific research, domestic sales and export capabilities.
- The company’s OTC business generates approximately $1 million in revenue per quarter through its three major brands.
- Relevium has secured a C$1 million purchase order in Saudi Arabia, marking the company’s entrance into international markets like Latin America, Asia and the Middle East.
- 58 SKUs developed and 400 natural product numbers registered with Health Canada for BioGanix to date.
- Relevium has acquired Cannakids’ IP, a leader in medical cannabis patient research and pediatric and adult consumer product development.
- Relevium has partnered with SOS Cannabis Inc. to help medical cannabis patients seek retroactive and proactive reimbursement free of charge.
- International expansion plans for all brands.
The Global Cannabis, Nutraceutical and Wellness Markets
The global cannabis market is expected to surpass $31 billion by 2021. Growth of the market is attributed to the increasing number of countries around the world legalizing medical and recreational cannabis and the research being conducted into CBD. After the passing of the US Farm Bill, the country has been looking into other legislation that will foster the domestic growth of the cannabis and CBD markets.
In 2017, the global wellness market reached $4.2 trillion. Within that, $1.08 trillion is attributed to the personal care, beauty and anti-aging sector and $575 billion is attributed to the preventative and personalized medicine and public health sector. As the global cannabis market grows, analysts are expecting these sectors to continue performing well in the coming years.
Another market that Relevium is targeting is the global nutraceutical market which is set to reach US$578.23 billion by 2025. The market is set to grow due to an increased demand for healthy foods and high-performance natural ingredients in nutraceutical products. The nutraceutical market has also adopted e-commerce and social media platforms as a way to market their products and increase awareness about health-related topics.
BioGanix: Serving the Americas
Relevium’s wholly-owned subsidiary, BGX e-Health LLC, is a nutraceutical company that develops a variety of weight-loss, health, beauty and fitness supplements and products. The company is becoming one of the leading dietary supplements brands in the US due to its high-quality products. BioGanix currently drives Relevium’s revenue generation, creating approximately $1 million in revenue per quarter.
Since acquiring the BioGanix brand, Relevium has expanded its product lines and distribution channels across the US. Consumers can find BioGanix-branded products online through Walmart.com and Amazon.co.uk. The company offers a total of 58 SKUs and has registered 400 natural product numbers with Health Canada under its BioGanix brand, with plans to roll-out the brand throughout Europe and Canada in 2020.
Brands and Products
The BioGanix brand offers a variety of supplements and nutraceutical products through Amazon, eBay (NASDAQ:EBAY) and Walmart. The brand’s gold series products are available in the US and Europe. Relevium has released a total of eight SKUs and intends to release an additional 30 SKUs to market in the near term.
“Following an initial market testing period, we are now expanding our presence in walmart.com to over 30 SKUs and we are targeting the walmart.ca platform for the initial launch of the Bioganix® Gold Series brand into the Canadian market,” said Relevium’s former Chief Marketing Officer Abis Hussain.
Curaloe Premium Aloe Vera
Relevium has launched a smaller brand under Bioganix ®, which is manufactured in the Caribbean with premium organic aloe vera. The brand features a range of aloe vera-based products such as supplements and skincare products that can be formulated with other plant derivatives such as hemp, ashwagandha and tart cherries.
There are over 420 aloe vera species in the Liliaceae family, which produces the well-known aloe vera gel. Aloe vera gel is used in a variety of conventional and natural products. The plant also contains 75 components with other health benefits such as vitamins, amino acids, enzymes, polysaccharides, saponins and salicylic acids. Aloe also provides 20 out of the 22 human-required amino acids.
Push and Pull System™
Relevium has also launched its Push and Pull System™, an innovative technology that offers a comprehensive skincare solution. The natural anti-aging system combines collagen protein supplements and aloe vera-based anti-aging cream. Relevium intends to target Hispanic women in the US as they spend four times as much as Caucasian women on health and beauty products.
“The launch of Push and Pull System™ in the fastest-growing segment of the health and wellness market represents a major milestone for Relevium. The launch of the system in the US Hispanic market provides a focused and disciplined new approach to tailoring product offerings to customer needs of a potentially highly responsive market,” said Useche.
Relevium intends to roll out its Push and Pull System™ in Latin America. The company has retained Latin model and TV personality Daniela Kosan to act as its spokesperson in Latin America to aid in the sale of its Push and Pull System™ and other products. The company is also looking to sell its system in south Florida, Texas, California and Mexico.
Heart and vision care products
Relevium launched a new line of omega fish oil-based formulations that target inflammation, heart and vision care. The two formulated products, CardiaPro™ and VisionPro™, target inflammation to support specific health functions, such as heart activity and vision.
“We have started the process of shifting towards scientific-based formulations, targeting niche and focused product offerings in high demand, such as the case of inflammation,” stated Mr. Hussain. “Our heart and vision formulations will be sold primarily through social media and through some of our major market places. However, we are also pursuing a brick and click strategy thus extending our offering through health stores.”
Partnerships and Agreements
Bio V Pharma
Relevium has entered into a manufacturing agreement with Bio V Pharma Inc., a Quebec-based, full-service manufacturer of pharmaceutical and nutraceutical products to manufacture, label and package Bioganix ® products for sale in Canada by Q1 2020. The deal is expected to provide Relevium with relationships with major brick and mortar retailers as well as the international markets.
Through an LOI, Relevium plans to roll its interest in BGX e-Health into Newscope Capital Corporation to unlock the value of its subsidiary. Newscope is a British Columbia- based, privately-held company looking to enter the wellness, CBD and hemp industries through this acquisition and by completing its listing on the CSE in 2020. Under the terms of the agreement, Relevium is expected to receive 20 million Newscope shares at $0.50 per share. The value of the transaction is expected to total C$10 million.
Innova Health Care of Saudi Arabia
In October 2019, Relevium received a purchase order to supply Innova Health Care of Saudi Arabia with generic formulations totaling over C$1 million, marking the company’s entrance into the overseas markets in Latin America, Asia and the Middle East. Relevium believes the Middle East can present numerous near-term revenue growth opportunities. According to Mordor Intelligence, the global biopharma market is expected to reach US$388.9 billion by 2024.
Contract Manufacturing Company
To help the company fulfill its manufacturing contracts, Relevium has executed an LOI to acquire a Montreal-based biopharma contract manufacturing company. The Montreal-based company offers private and white label manufacturing for its brands and over the counter products that are sold throughout the US and Canada.
With the acquisition, Relevium has established a vertically-integrated operation for its subsidiary, BGX e-Health. It also could have a material impact on BGX e-Health’s revenues and gross margins while also providing lucrative news opportunities, such as private label solutions in North America and product R&D.
Biocannabix: Serving International Markets
Relevium’s wholly-owned subsidiary Biocannabix is focused on serving the pediatric and adult medical markets with nutraceutical and pharmaceutical cannabis-based products. Through its subsidiary, Relevium has developed two brands and is currently in the process of acquiring a late-stage applicant for standard processing and medical sales license located in Montreal, Quebec. The facility is currently being built to EU-GMP standards. Weedsense intends to be fully licensed by the middle of 2020 and obtain EU-GMP certification shortly thereafter.
Biocannabix has signed an agreement to acquire WeedSense, a late-stage applicant for medical sales and standard processing. Through the deal, Relevium’s subsidiary Biocannabix can gain the ability to import, export, warehouse, package and sell endo-medical nutraceuticals and medical food products through pharmacies and hospitals within the Canadian marketplace. The company intends to distribute endo-medical cannabis products for the pediatric market in Canada. Biocannabix will not be competing on a large scale but plans to focus on serving niche markets with its specifically formulated cannabis products.
Biocannabix is in the process of acquiring the shares of Lifeline Pharma SAS, a Cali-based cultivation and extraction company in Colombia. Lifeline is currently in the process of securing three licenses; extraction and manufacturing, cultivation with THC and non-psychoactive cultivation. These licenses also allow for scientific research, domestic sales and export capabilities.
The acquisition of Lifeline is expected to provide Biocannabix with 100 percent organically-grown cannabis with access to over 600 registered genetic strains and a stage two flower capacity of approximately 170,000 kilograms per year at an estimated cost of $0.53 per gram. The deal is also expected to provide the company with the opportunity to build out an EU-GMP extraction facility and the ability to trace and audit the process through blockchain technology.
Lifeline’s facility is located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave, seven minutes away from the international airport. The property is 10 minutes away from Cali’s downtown core which boasts a population of over three million people.
The facility is expected to be developed in three stages. The initial five hectares contain local offices, a laboratory, a fully-enclosed greenhouse and 200,000-square-feet of open-air greenhouses. Lifeline has the option to expand the facility up to 2.2 million-square-feet of open-air greenhouses or up to 6.5 million-square-feet of cultivation space.
Relevium has partnered with SOS Cannabis, a multi-disciplinary law firm headquartered in Québec, Canada that helps medical cannabis patients seek retroactive and proactive reimbursement. Through the partnership, Relevium intends to provide its pediatric customers with the ability to obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy.
“As we prepare to enter the pediatric endo-medicinal market in Canada with an initial 10 CannaKids® formulated products, not only are we providing parents with a natural alternative and/or health support mechanism, but now we are able to provide them with the ability to seek reimbursement from governmental agencies without any costs,” said Useche.
In May 2019, Relevium an exclusive Canadian IP license from Cannakids. The license allows Relevium to build upon Cannakids’ existing infrastructure and standard operating procedures as the company rolls out the brand in Canada and expands Cannakids’ patient network. There is a 13 percent royalty on any sales made on Cannakids’ products in Canada.
Cannakids is a leader in medical cannabis patient research as well as pediatric and adult consumer product development. The company has an extensive patient network and a network of trained nurses, pediatric and adult dosing experts, medical doctors and leading researchers in the US and Israel.
Cannakids distributes its products through a growing network of licensed retail locations throughout California. Cannakids intends to expand its presence throughout the US and into international markets.
“With over four years of research, patient data and passion behind the real-life success stories with pediatric and adult patients, our investment in Cannakids is highly strategic and accretive to our shareholders,” said Useche. “We are proud to be business partners with Tracy Ryan and her team of talented and passionate professionals and we look forward to a solid and mutually rewarding relationship.”
In December 2018, Relevium initially launched three of its LeefyLyfe hemp-based products in the UK on a pre-order basis. The company intends to launch several additional exclusive formulations as sales expand throughout Europe. Relevium launched the LeefyLyfe brand in the US in November 2019, which featured a comprehensive line of organic health and wellness hemp products.
Relevium’s Management Team
Aurelio Useche — Director and CEO
Aurelio Useche leverages over 20 years of senior management experience including COO, CFO and CEO in several private and publicly traded corporations in manufacturing, mining exploration, consumer goods and entertainment. He is a CPA, CMA and a graduate of the executive MBA program at Queen’s University School of Business. He is also a graduate of the Corporate Directors program at the University of Toronto’s Rotman School of Business and of the Masters Certificate program in Risk Management program at York University’s Schulich School of Business.
Mark Billings – CFO
Mark Billings is an experienced executive Chartered Financial Analyst and a graduate of the Harvard School of Business. He has founded and managed companies in the junior resource sector, where he acted as CEO, CFO and board member. He serves on the board of several publicly-traded resource companies in Canada and abroad. In addition to his executive career, Billings has been an investment banker, having raised hundreds of millions of dollars for small-cap companies, including several junior mining companies.
Dr. Tina Sampalis — Director
Dr. Tina Sampalis is the founder and President of the Agoo Children’s Health and Wellness Centers and President of Vanguard Strategic Consulting. She is an oncology surgeon trained in physiology, dermatology and pediatrics. In addition to her medical career, Dr. Sampalis is also a leading researcher known for her work in the development of evidence-based nutraceuticals, including Neptune Technologies & Bioressources, where she discovered one of the primary reasons’ krill oil is so beneficial to human health: phospholipids. Dr. Sampalis is the named inventor of Neptune’s composition and application patents. As the former President of Acasti Pharma Inc., she led the development of a novel patented active pharmaceutical ingredient targeting the prevention and treatment of hypertriglyceridemia and cardio metabolic-disorders.
Andre Godin — Director and Chairman
Andre Godin is currently Executive Vice-President and Chief Financial Officer at IntelGenx. He has more than 25 years of experience in the biotech-pharma industry. He has a strong background in capital markets, finance and operations. He held several high-level positions such as CEO, CFO and Vice-President of pharmaceutical and nutraceutical companies. Godin is a member of the Canadian Chartered Professional Accountants and the Canadian Institute of Chartered Accountants. He holds a Bachelor of Business Administration degree from Université du Québec à Montreal.
Michel Timperio — Director
Michel Timperio currently holds the position of President of the Cannabis Business and Head of Strategic Development at Neptune Wellness. He has been employed by Neptune since 2010, and served as chairman and member of the Board of Directors from 2000 to 2008. He obtained his Bachelor of Commerce at Concordia University in Montreal, Quebec. With a natural entrepreneurial character, he launched his own distributing business. Many years later, Timperio built a start-up venture in residential construction from 2001–2010. He has worked for large corporations, including Armstrong World Industries and Reichhold Chemicals, where he held senior management business development positions. He has also retained a political career for six years.
Pierre Bertrand — Director
Pierre Bertrand, President of Essilor Canada, is a senior executive with international experience in Marketing, Finance and Manufacturing, including multiple years of award-winning Marketing and Brand Management and proven track record of excellence in financial roles eye health, pharmaceutical and biotechnology. Pierre holds an MBA from the University of Windsor and a BA from the University of Concordia.
*Disclaimer: This profile is sponsored by Relevium Technologies Inc. (TSXV:RLV,OTCQB:RLLVF,FWB:6BX). This profile provides information which was sourced by the Investing News Network (INN) and approved by Relevium Technologies Inc., in order to help investors learn more about the company. Relevium Technologies Inc. is a client of INN. The company’s campaign fees pay for INN to create and update this profile.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Relevium Technologies Inc. and seek advice from a qualified investment advisor.